Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab <i>Versus</i> Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study
Although Atez/Bev and LEN confer similar survival in BCLC-B HCC, lenvatinib offers superior cost-effectiveness in the Japanese healthcare setting. These findings underscore the importance of integrating economic considerations into treatment selection for intermediate-stage HCC.
Authors
- Kenta Motomura (ORCID: https://orcid.org/0000-0002-7515-099X)
- Hideo Suzuki (ORCID: https://orcid.org/0000-0002-1469-7449)
- Kazuki Kurosaka
- Kosuke Tanaka (ORCID: https://orcid.org/0000-0002-5285-939X)
- Masayoshi Yada (ORCID: https://orcid.org/0000-0002-1129-5380)
- Akifumi Kuwano (ORCID: https://orcid.org/0000-0001-9397-8056)
- Taikan Hamomoto
Institutions
- Ichinomiya Kenshin College (JP)
- Aso Iizuka Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-09-26
- DOI
- https://doi.org/10.21873/anticanres.17808
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00